Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Givastomig Combo Shows Early Promise in CLDN18.2+ Gastric, Esophageal, GEJ Adenocarcinoma

July 2nd 2025

Givastomig paired with chemoimmunotherapy was tolerable and elicited responses in CLDN18.2+ gastric, esophageal, and GEJ cancers.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC

June 30th 2025

China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.

FDA Grants Breakthrough Therapy Designation to Daraxonrasib for KRAS G12X-Mutant Metastatic PDAC

June 29th 2025

Daraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

FDA Grants Accelerated Approval to Dato-DXd for EGFR+ NSCLC

June 23rd 2025

The FDA approved Dato-DXd for previously treated, locally advanced or metastatic, EGFR-mutated non–small cell lung cancer.

PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test

June 19th 2025

Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.

Five Under 5: Top Oncology Videos for the Week of 6/8

June 15th 2025

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

TT125-802 Demonstrates Potential in Advanced NSCLC and Solid Tumors

June 13th 2025

TT125-802 demonstrated early clinical activity and a favorable safety profile in advanced solid tumors.

FDA Approves Taletrectinib for ROS1+ Advanced NSCLC

June 11th 2025

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.

The OncFive: Top Oncology Updates for the Week of 6/1

June 7th 2025

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

FDA Grants Priority Review to Ziftomenib in NPM1-Mutant R/R AML

June 2nd 2025

The FDA has granted priority review to ziftomenib for relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.

MK-1084 Yields Responses With Manageable Safety in KRAS G12C+ CRC

May 31st 2025

MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.

Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC

May 31st 2025

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30th 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer

May 28th 2025

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

Full FDA Approval Underscores the Role of Larotrectinib in NTRK Fusion+ Solid Tumors

May 27th 2025

David S. Hong, MD, discusses the full FDA approval of larotrectinib for NTRK fusion–positive solid tumors.

Early Insights from ASCO 2025: Press Briefing Highlights with Clinical Impact

May 26th 2025

A 2025 ASCO press briefing previewed key advances in breast and lung cancer, HER2 diagnostics, and GLP-1s’ link to reduced cancer risk.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.